DJIA 16,790.19 13.76 0.08%
NASDAQ 4,748.36 -32.90 -0.69%
S&P 500 1,979.92 -7.13 -0.36%
market minute promo


141.22 -2.58 (-1.79%)

REAL-TIME: Last trade at

Extended Hours: $141.19 -$0.03 (-0.02%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

AMGN $141.22 -1.79%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $142.12
Previous Close $143.80
Daily Range $138.06 - $143.37
52-Week Range $127.67 - $181.81
Market Cap $107.1B
P/E Ratio 19.05
Dividend (Yield) $3.16 (2.2%)
Ex-Dividend Date
Dividend Pay Date
Volume 4,734,743
Average Daily Volume 4,603,762
Current FY EPS $9.73




Drug Makers

Amgen (AMGN) Description

A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. Website:

News & Commentary

3 Rock-Solid Dividend Stocks You Can Buy Right Now

Looking for dependable income? Here are 3 healthcare stocks that we think you can count on to be reliable dividend payers for years to come.

4 Pharma Stocks Gaining from High Pricing Power

My Third Quarter 2015 Portfolio Review - Doing Some Buying

Who Wins and Loses with the TPP?

Novartis' (NVS) Sandoz Files for Enbrel Biosimilar in the U.S.

Quirky Or Sensible? Weighting A Dividend Growth Portfolio By Quality And Income

The Case For A Biotech-Bonds Barbell Strategy: Focus On Several Junior Biotech Stocks

iShares U.S. Healthcare ETF Experiences Big Outflow

Health Care Sector Update for 10/02/2015: CHRS,AMGN,XNPT,FOLD

Amgen Is In Novartis' Crosshair

After winning approval for a biosimilar to Amgen's Neupogen, Novartis has filed for approval of another biosimilar. This time its target is Amgen's Enbrel.

See More AMGN News...

AMGN's Top Competitors

AMGN $141.22 (-1.79%)
Current stock: AMGN
GILD $97.54 (-1.73%)
Current stock: GILD
CELG $112.19 (-3.80%)
Current stock: CELG
$0.00 (0.00%)
Current stock: